Initiation of Antiretroviral Therapy
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Perelson AS, Neumann AU, Markowitz M, et al. HIV dynamics in vivo: virion clearance, rate, infected cell life - span, and viral generation time. Science 1996;271:1582-5.
Schacker T, Collier A, Hughes J, et al. Clinical and epidemiologic features of primary infection. Ann Intern Med 1996;125:257-64.
Kinloch-de Loes S, de Saussure P, Saurat J, et al. Symptomatic primary infection due to human immuno-deficiency virus type-I : review of 31 cases. Clin In-fect Dis 1993;17:59-65.
Tindall B, Cooper D. Primary HIV infection: host responses and intervention strategies. AIDS 1991;5:1-14.
Niu M, Stein D, Schnittman S. Primary human immu-nodeficiency virus type I infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993;168:1490-501.
Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV - infection. N Engl J Med 1991:324:954-60.
Farzadegan H, Henrard DR, Kleeberger CA, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-seroconversion. J Acquir Immune Defic Synd 1996;13:448-55.
Perelson A, Essunger Y, Cao Y, et al. Decay characteristics of HIV- infected compartment during combination therapy. Nature 1997;387:188-91.
Hoen B, Harzic M, Fleury H, et al. ANR 5053 trial of Zidovudine, Lamivudine and Ritonavir combination in patients with symptomatic primary HIV - infection : preliminary results. 4th conference on Retroviruses and opportunistic infections. Washington DC, Jan 22-26, 1997 ; Abstract 232 p. 107.
Tamalet C, Poizot Martin I, La Feuillade A. et al. Viral load and genotypic resistance pattern in HIV infected patients treated by a triple combination therapy including nucleoside and protease inhibitors initiated at primary infection. 4th conference on Retroviruses and
opportunistic infections. Washington DC, Jan 22 - 26, 1997 ; Abstract 592 p. 174.
Perrin L, Markowitz M, Calandra G, et al. An open treatment study of acute HIV infection with Zidovudine, Lamivudine and Indinavir sulfate. 4th conference on Retroviruses and opportunistic infections. Washington DC, Jan 22 - 26, 1997 ; Abstract 238 p. 108.
Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus Indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Section. N Engl J Med 1997;337:725-33.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with Indinavir, Zidovudine and Lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
De Jong M, Vella S, Carr A, et al. High – dose Nevirapine in previously untreated human immunodefi-ciency virus type-I infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-70.
Eron J, Benoit S, Jemsek J, et al. Treatment with nivudine, Zidovudine or both in HIV - positive patients with 200 to 500 CD4 cell per cubic millimeter. N Engl J Med 1995;333:1662-9.
Staszewski S, Loveday C, Picazo J, et al. Safe and effecacy of Lamivudine – Zidovudine combination therapy in Zidovudine - experienced patients. JAMA 1996; 276:111-7.
Schapiro J, Winters M, Stewart F, et al. The effect of high-dose Saquinavir on viral load and CD4 T – cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
Bartlett J. Protease inhibitors for HIV infection. Ann Intern Med 1996;124:1086-8.